Surgery

Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case

Retrieved on: 
Wednesday, April 3, 2024
Organogenesis, District court, Surgery, Regenerative medicine, Court, Prejudice

CANTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that on March 29, 2024, the United States District Court for the Eastern District of New York granted, with prejudice, the Company’s motion to dismiss all claims asserted.

Key Points: 
  • CANTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that on March 29, 2024, the United States District Court for the Eastern District of New York granted, with prejudice, the Company’s motion to dismiss all claims asserted.
  • “We are very pleased with the Court's decision,” said Lori Freedman, Chief Administrative and Legal Officer for Organogenesis.
  • “We are happy to have this behind us so we can continue to focus on our mission to substantially improve patient outcomes while lowering the overall cost of care.”

Emet Surgical Accepted into Innosphere Ventures Life Sciences Incubator Program

Retrieved on: 
Tuesday, April 9, 2024
Oncology, Medical Devices, Health, Surgery, Other Health, General Health, U.S. FDA, ROI, Entrepreneurship, Cancer, Surgeon, Ecosystem, Pathology, Orientation

Emet Surgical , developers of innovative tools to improve surgery outcomes, today announced its acceptance into the Innosphere Ventures Life Sciences Incubator for pioneering startups, a program of impact nonprofit Innosphere Ventures .

Key Points: 
  • Emet Surgical , developers of innovative tools to improve surgery outcomes, today announced its acceptance into the Innosphere Ventures Life Sciences Incubator for pioneering startups, a program of impact nonprofit Innosphere Ventures .
  • Innosphere’s incubation programs support the commercialization efforts of entrepreneurs, technical founders and university researchers who are launching and scaling high-tech startups.
  • The Innosphere Ventures Regional Life Sciences Incubator accelerates the success of founders building technology and science-based companies through its incubation programs, office and specialized wet laboratory facilities, and venture capital funds.
  • "Emet Surgical’s innovative approach to improving surgery outcomes, born out of firsthand experience and a commitment to addressing critical challenges in the field, exemplifies the spirit of entrepreneurship and innovation that defines our cohort,” said Kevin Noble, Life Sciences Program Director for Innosphere.

OM1 and Medtronic Partner on Propel Study to Assess Long-term Outcomes for Patients With Chronic Rhinosinusitis

Retrieved on: 
Tuesday, April 9, 2024
Data Management, Technology, Other Health, Health, General Health, Pharmaceutical, Health Technology, Research, Artificial Intelligence, Surgery, Science, University Challenge 2013–14, Partnership, Physician, Inflammation, Patient, American Academy, Standard of care, CRS, AI, Medtronic, PROPEL, ENT, Sinusitis, ESS, Adhesion, Pharmaceutical industry

The study focused on healthcare resource use (HCRU) and long-term outcomes in patients with chronic rhinosinusitis (CRS) who underwent endoscopic sinus surgery (ESS).

Key Points: 
  • The study focused on healthcare resource use (HCRU) and long-term outcomes in patients with chronic rhinosinusitis (CRS) who underwent endoscopic sinus surgery (ESS).
  • The study found that PROPEL devices are associated with lower HCRU and revision surgery during a 24-month follow-up period after ESS.
  • Thus, the use of PROPEL devices may lead to payer savings from reduced healthcare resource utilization.
  • “The results of this study demonstrate a rare win-win-win within healthcare,” said Amy Van Sach, president of Medtronic ENT.

SimBioSys Launches TumorSight Plan, A Pioneering Clinical Decision Support for Early-Stage Breast Cancer

Retrieved on: 
Tuesday, April 9, 2024
Technology, Biotechnology, Health, Consumer, Other Health, Radiology, Surgery, Artificial Intelligence, Oncology, Medical Devices, Software, General Health, Health Technology, Women, Breast cancer, MRI, Breast Cancer Care, Mastectomy, Science, Patient, Artificial intelligence, 3D, Cancer, Surgeon, Woman, Risk assessment, CMO, Simbiosys, FDA, Medicine, Medical imaging

Now, with TumorSight Plan, surgeons are empowered with visualization, data-driven insights, and best-practices to help support more effective provider-patient interactions and individualize treatment planning to right-size care.

Key Points: 
  • Now, with TumorSight Plan, surgeons are empowered with visualization, data-driven insights, and best-practices to help support more effective provider-patient interactions and individualize treatment planning to right-size care.
  • TumorSight Plan is powered by the FDA-cleared TumorSight Viz , an innovative 3D visualization solution to support the rapidly increasing use of MRI imaging in Breast Cancer.
  • SimBioSys’ TumorSight suite is a huge breakthrough in our capacity to utilize AI to calibrate a balance between decision standardization and individualized medicine.
  • TumorSight Plan gives the breast cancer surgeon a platform and opportunity to enable more analytical patient-centric decision making which should lead to higher percentage of women undergoing breast conservation surgery.”

CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting

Retrieved on: 
Tuesday, April 9, 2024
Health, Surgery, Genetics, Managed Care, General Health, Cardiology, Biotechnology, Patient, International Society, Caregiver, White, Transplant, Columbia University, University, University of Colorado, Lung transplantation, Heart transplantation, Abstract, Lung, Heart, NYU Langone Health, Stanford University, University Health Network, MAS, Loyola University, Medical device

CareDx, along with study collaborators from leading transplant centers, will present cutting-edge developments that underscore the clinical significance of CareDx’s cardiothoracic portfolio.

Key Points: 
  • CareDx, along with study collaborators from leading transplant centers, will present cutting-edge developments that underscore the clinical significance of CareDx’s cardiothoracic portfolio.
  • This includes AlloSure Heart, AlloMap Heart, HeartCare, AlloSure Lung, and AiCAV (in development); featured in over 25 oral presentations, posters, and two symposia.
  • These presentations will highlight real-world applications driving advancements in heart and lung transplantation.
  • “We are proud to have a leading presence once again at this pivotal heart and lung transplant meeting.

The OneLegacy Donate Life Run/Walk and Family Festival Returns to Azusa Pacific University, Celebrating 22 Years of Inspiring Southern Californians to Donate Life

Retrieved on: 
Monday, April 8, 2024
Entertainment, Sports, General Health, Events, Concerts, Family, Philanthropy, Consumer, Fund Raising, Foundation, Surgery, Health, Running, Research, Foreign policy, Friends, ABC, Cedars-Sinai Medical Center, Memory, Azusa Pacific University, Thermo Fisher Scientific, City, Hospital, Providence St. Joseph Health, Life, Eye, Golden Joystick Awards, Mexican cuisine, Medical device

“We look forward to welcoming donor families, grateful recipients, living donors and OneLegacy’s hospital and community partners to our 22nd Annual Run/Walk and Family Festival,” said Tom Mone, External Affairs Officer for OneLegacy.

Key Points: 
  • “We look forward to welcoming donor families, grateful recipients, living donors and OneLegacy’s hospital and community partners to our 22nd Annual Run/Walk and Family Festival,” said Tom Mone, External Affairs Officer for OneLegacy.
  • “The OneLegacy Donate Life Run/Walk is a special celebration of the gift of life and the power of organ, eye and tissue donation within our local communities.”
    The OneLegacy Donate Life Run/Walk will include a special opening ceremony, hosted by Phillip Palmer and Gabriela Teissier.
  • 2024 will be the 9th year that team Forever 22 will participate in the OneLegacy Donate Life Run/Walk.
  • All proceeds from the Donate Life Run/Walk will benefit the OneLegacy Foundation, with the goal to enhance OneLegacy’s public education efforts and inspire local communities to donate life.

Vicarious Surgical to Report First Quarter 2024 Financial Results on April 29, 2024

Retrieved on: 
Monday, April 8, 2024
Robotics, Health, Medical Devices, Technology, Surgery, Health Technology, Other Technology

Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced it will report financial results for the first quarter ended March 31, 2024 after the market closes on Monday, April 29, 2024.

Key Points: 
  • Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced it will report financial results for the first quarter ended March 31, 2024 after the market closes on Monday, April 29, 2024.
  • Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
  • Investors interested in listening to the conference call may do so by dialing +1 833 470 1428 for domestic callers or +1 404 975 4839 for international callers, using access code: 061323.
  • A live and archived webcast of the event will be available at https://investor.vicarioussurgical.com .

PanTher Therapeutics Presents Positive First-in-Human Data for PTM-101 in Pancreatic Cancer at AACR Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Oncology, Health, Surgery, Clinical Trials, Pharmaceutical, Biotechnology, Toxicity, Infection, Associate, Patient, Cancer, Doctor of Philosophy, MD, Panther, AACR, Pancreatic cancer, Neoplasm, Clinical trial, Therapy, Paclitaxel, Pancreas, Pancreatitis, Safety, Monash University, Prognosis, Pharmaceutical industry

PTM-101 was placed directly onto the pancreas, overlying the location of the tumor using standard laparoscopic equipment as part of a disease staging assessment.

Key Points: 
  • PTM-101 was placed directly onto the pancreas, overlying the location of the tumor using standard laparoscopic equipment as part of a disease staging assessment.
  • Once in place over the tumor site, PTM-101 locally delivered a sustained dose of the chemotherapeutic agent over four weeks.
  • Approximately three weeks after placement of PTM-101, all participants began standard of care therapy, which included treatment with mFOLFIRINOX.
  • Results of the clinical trial demonstrated that PTM-101 reduced the size of pancreatic tumors in all three patients.

Propanc Biopharma’s CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic Financing

Retrieved on: 
Monday, April 8, 2024
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Clinical Trials, Science, Surgery, Biotechnology, FDA, Health, OTC Markets Group, Communication, AP, PPCB, Corporate title, Patient, Cancer, APS, Atmosphere, Drug development, Safety, Due diligence, Pharmaceutical industry

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company’s CEO, Mr. James Nathanielsz, shares his views on revolutionizing cancer treatment with an inside look at drug development and strategic financing.

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company’s CEO, Mr. James Nathanielsz, shares his views on revolutionizing cancer treatment with an inside look at drug development and strategic financing.
  • Mr. Nathanielsz appeared on a show with Mr. Joel Block, a weekly podcast on killer business strategies and how the best leaders make them work.
  • In this week’s episode, Mr. Nathanielsz discusses the competitive advantage of the Company and its enzyme treatment for metastatic cancer.
  • Some key points to the competitive advantage highlighted by Mr. Nathanielsz include:
    Global Financing Strategy: Mr. Nathanielsz emphasizes the company's global view on accessing funds and its current pursuit of series A financing, showcasing a strategic approach to securing financial support.

AffyImmune Therapeutics Announces Clinical and Regulatory Advisory Board to Support Development of AIC100 in Solid Tumors

Retrieved on: 
Monday, April 8, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Other Health, Clinical research, Harvard Medical School, Melanoma Research, Translational research, Surgery, Clinical, Associate, George Washington University, Patient, Regulatory affairs, University, Cancer, Doctor of Philosophy, Melanoma, Brown University, Translation, Treatment, Therapy, Drug development, Safety, FACS, University of Southern California, Biomedical Research, Pathology, Research fellow, School, Pharmaceutical industry

The CRAB will provide strategic counsel and expertise as AffyImmune advances its affinity-tuned CAR T therapeutics in clinical development.

Key Points: 
  • The CRAB will provide strategic counsel and expertise as AffyImmune advances its affinity-tuned CAR T therapeutics in clinical development.
  • “This group of distinguished scientists and advisors bring to AffyImmune invaluable CAR T drug development experience from research to commercialization,” said Sonal Gupta, MD, PhD, AffyImmune SVP and Head of Clinical Development.
  • ‘’I am honored to join Affylmmune’s Clinical and Regulatory Advisory Board and look forward to working with the other members to advance the development of novel treatments,” said Carmelo Nucera, MD, PhD.
  • Jorge J. Nieva, MD , Associate Professor of Clinical Medicine, Keck School of Medicine, University of Southern California and Section Head, Solid Tumors, USC/Norris Cancer Center.